Patient-Centered Surgical Prehabilitation
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT05715684
- Status
- Recruiting
Conditions
- Bladder Cancer
- Cystectomy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Accepted
Interventions
- Exercise Training — OTHERVirtually supervised exercise training for four weeks prior to cystectomy
- Nutritional Intervention — DIETARY_SUPPLEMENTPatients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
Study Details
The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nutritionally for the cystectomy procedure.
Key Dates
- Start date
- Mar 1, 2023
- Status verified
- Mar 2023
- Primary completion
- Dec 27, 2026
- Completion
- Dec 25, 2027
Study Design
- Enrollment
- 25 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Other: Standard treatment PlanThis is the main arm of the study in which all 25 anticipated participants will be enrolled into.
Primary Outcome Measure
Total days hospitalized within 30-days of surgery [ Time Frame: 60 months ]
Central Contacts
- Matthew Mossanen, MD, MPH617-732-6384
- Nnamdi Onochie6175258753
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Matthew Mossanen, MD (PRINCIPAL_INVESTIGATOR) |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | Matthew Mossanen, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
By condition
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery ProtocolPHASE3 · Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderPHASE1/PHASE2 · Recruiting · Noah Hahn, M.D. · Phoenix, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama